Education
About Us
Working with TipRanks
Follow Us
Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ:VNDA
VNDA Stock Chart & Stats
$4.41
-$0.20(-4.12%)
At close: 4:00 PM EST
$4.41
-$0.20(-4.12%)
Day’s Range― - ―
52-Week Range$3.81 - $5.70
Previous CloseN/A
Volume240.10K
Average Volume (3M)664.21K
Market Cap
$260.62M
Enterprise Value$12.03M
Total Cash (Recent Filing)$293.75M
Total Debt (Recent Filing)$6.23M
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Feb 11, 2026EPS Estimate
-0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding59,096,630
10 Day Avg. Volume867,153
30 Day Avg. Volume664,213
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.52
Price to Sales (P/S)1.40
P/FCF Ratio-17.14
Enterprise Value/Market Cap0.05
Enterprise Value/Revenue0.06
Enterprise Value/Gross Profit0.24
Enterprise Value/Ebitda-0.12
Forecast
1Y Price Target
$15.50Price Target Upside251.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.69
Revenue Forecast (FY)$221.34M
Bulls Say, Bears Say
Bulls Say
Drug ApprovalsKey elements that could result in near-term drug approvals include expedited re-review by the FDA of Vanda's New Drug Application for tradipitant in motion sickness and approval decision dates for other drugs.
Legal And Regulatory DevelopmentsA crucial legal win may signal additional upside not factored into forecasts.
Market ExclusivityOrphan Drug status provides, among other things, seven-year market exclusivity from the date of approval.
Bears Say
Financial PerformanceVanda reported a net loss of $0.38 per share, moderately wider than our forecast for a net loss of only $0.31 per share; this was mainly due to higher-than-anticipated operating expenses.
Revenue ConcernsQuarterly revenue weak, operating expenses higher than expected—however, focus remains on regulatory outlook.
Valuation AssessmentWe remind investors that we do not include any contribution from any components of Vanda's early-stage pipeline in our valuation assessment.
Vanda News
VNDA FAQ
What was Vanda Pharmaceuticals Inc.’s price range in the past 12 months?
Vanda Pharmaceuticals Inc. lowest stock price was $3.81 and its highest was $5.70 in the past 12 months.
What is Vanda Pharmaceuticals Inc.’s market cap?
Vanda Pharmaceuticals Inc.’s market cap is $260.62M.
When is Vanda Pharmaceuticals Inc.’s upcoming earnings report date?
Vanda Pharmaceuticals Inc.’s upcoming earnings report date is Feb 11, 2026 which is in 90 days.
How were Vanda Pharmaceuticals Inc.’s earnings last quarter?
Vanda Pharmaceuticals Inc. released its earnings results on Oct 29, 2025. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.433 by $0.053.
Is Vanda Pharmaceuticals Inc. overvalued?
According to Wall Street analysts Vanda Pharmaceuticals Inc.’s price is currently Undervalued.
Does Vanda Pharmaceuticals Inc. pay dividends?
Vanda Pharmaceuticals Inc. does not currently pay dividends.
What is Vanda Pharmaceuticals Inc.’s EPS estimate?
Vanda Pharmaceuticals Inc.’s EPS estimate is -0.96.
How many shares outstanding does Vanda Pharmaceuticals Inc. have?
Vanda Pharmaceuticals Inc. has 59,096,630 shares outstanding.
What happened to Vanda Pharmaceuticals Inc.’s price movement after its last earnings report?
Vanda Pharmaceuticals Inc. reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.433. Following the earnings report the stock price went down -20.148%.
Which hedge fund is a major shareholder of Vanda Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in VNDA
Vanda Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.50 (251.47% Upside)
$15.50 (251.47% Upside)
Blogger Sentiment
Bullish
VNDA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 17.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-18.33%
12-Months-Change
Fundamentals
Return on Equity
-16.72%
Trailing 12-Months
Asset Growth
-6.82%
Trailing 12-Months
Company Description
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
VNDA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong commercial execution and pipeline advancements, with significant growth in Fanapt sales and strategic investments in infrastructure. However, the financial performance was marred by a significant net loss and increased operating expenses. Overall, the positives in sales and pipeline progression were balanced by financial challenges.View all VNDA earnings summariesVNDA Stock 12 Month Forecast
Average Price Target
$15.50
▲(251.47% Upside)
Technical Analysis
Ownership Overview
7.36% Insiders
16.12% Mutual Funds
0.32% Other Institutional Investors
63.54% Public Companies and
Individual Investors